Annual Report Highlights FY 13-14 - REC

Company’s financial history suggests that companies source of funding has changed in the last 10 years.  Company has become less dependent on government and more on the bond market and foreign currency.  Others like commercial paper, short term demand loans and term loans from banks fluctuate based on the need.  Exposure to foreign currency borrowing could increase currency fluctuation risk. Of the 17,621 crores foreign currency borrowing 11948 cr (67%) has been hedged and the remaining remains unhedged. Any wild currency swings will have considerable impact on the company earnings.

Annual Report Highlights FY 13-14 - Kovai Medical

Company has successfully performed liver transplant and heart transplant this year.  They are looking to perform lung transplant very soon.  Company intends to increase bed capacity and also expand in areas other than Coimbatore for which they have sought approval of borrowing limits of 1000cr.  Though demand for health care is likely to rise at above average levels, health care is a capital intensive business where the infrastructure needs constant upgradation which would mean lower free cash flows on average. Hospital is adding 150 beds 75 each for emergency and patient care.  It is also modernizing the Erode and city center facility and the total capex planned is at 80 cr.  Company also plans to open a new set up with 300 beds in Chennai at a cost of 300 cr. .  Funding is planned to be done with internal accrual, debt and equity .  Around 56% of the revenue came from Inpatients followed by almost equal contribution of 20% each from Outpatients and Pharmacy. Rest is from the dietary sales which is a meagre percentage.

Annual Report Highlights FY 13-14 - Zensar Technologies

On a consolidated basis, your Company has maintained steady growth with Total income of ` 2361.10 Crore.  The Consolidated Profit after Taxation was ` 237.53 Crore reflecting an increase of 36%. Global outsourcing market grew by 8.5% and the company grew by 9.5%.  Profitability was more due to increased profit margins 

Companies  vertical focus is in  Manufacturing, Retail, Banking, Financial Services and Insurance. Company has restructured verticals very recently to provide end to end solutions of the vertical and also to gain domain knowledge.

Annual Report Highlights FY 13-14 - HDFC BANK

Net Profit increased by 26% compared to previous year and was at 8478 cr. Total Deposits increased by  24% and advances by 26%. CAR was at 16%.  Gross NPA was at 0.98% of the advances.  At the end of FY total branches were at 3403 and ATMs at 11256.  Bank was available  at 2171 towns. Net Interest Margins were steady at 4.4% and RONW at 20%.  POS terminals installed was lower than last year and currently at 2.16 lacs. The debit cards numbers rose to 174 lacs however the credit card numbers came down to 51.4 lacs.  Around 65% or revenue is from interest income folowed by investments at 18% and then income through fees and comissions at 12%.

Annual Report Highlights FY 13-14 - HDFC

Individual loan approvals and disbursements grew by 16% and 21% respectively during the year. Average loan size was around 22lacs.  Individual loan book grew by 26% and the total loan book grew by 20%.  Of the total loan book, individual loans comprised of 71% of the portfolio. Company raised USD 300 million as external commercial borrowing for funding the low cost affordable housing projects. The principal amount of the loan has been hedged. Company also

Annual Report Highlights FY 13-14 - Axis Bank

Bank crossed the USD 1Billion mark (6217 cr) this year in net profits. 455 branches were opened this year in which 298 were in unbanked areas. Deposits grew by 11% and advances grew by 16%.  Net profit grew by 27%.  However the EPS growth was muted at 11% due to dilution of shares.  ROE stood at 18% which is lower than the average in the past 4 years. This again could be attributed to the equity dilution.  ROA stood healthy at 1.78%. Total number of branches and extensions stands at 2402 and the ATM were at 12922.  Bank is adequately capitalized BASEL III capital Adequacy Ratio (CAR) at 16% and Tier 1 CAR at 12%.

Annual Report Highlights FY 13-14 - Ajanta Pharma

It is currently ranked 39th in Indian formulations market concentrate in specialty formulations. Position improved from # 45 in 2013 to #39 this year. Company strategy is to manufacture value added products in niche therapy spaces addressing unmet patient needs.  It Improved its NPM from 8% in 2010 to 19% in 2014, ROCE from 14% in 2010 to 47% in 2010.  Currently company is 5th, 13th and 24th in the ophthalmological, dermatological and cardiological segments respectively in India